Volumetric
Volumetric, based in Houston, TX, specializes in advanced 3D bioprinting technologies for creating human tissues, focusing on applications in drug development, laboratory testing, and potentially building whole human organ replacements.
Company Overview
Volumetric is a company within the healthcare and industrial bio industries, focusing on breakthrough 3D bioprinting technologies. Founded in 2018 as a spin-out from Rice University, the company is headquartered in Houston, TX, USA, and has a team of five. Volumetric participated in the Y Combinator W20 batch and serves regions including the United States of America and America/Canada.
3D Bioprinting Technologies
Volumetric offers a suite of advanced 3D bioprinting technologies capable of constructing human tissue with intricate blood vessel networks. Their technology is designed to replicate specific functions of the human body, aiding in basic mechanistic biology, laboratory testing, screening, and drug development. The company's innovations are pivotal in the development of patient-specific tissues for drug safety and efficacy testing.
Human Organ Replacement
A significant focus for Volumetric is the development of whole human organ replacements made from patients' own cells. This innovation aims to provide tailor-made organ replacements, potentially transforming the landscape of organ transplantation and regenerative medicine.
Founding and Y Combinator Involvement
Volumetric was founded in 2018 as a spin-out from Rice University. The company gained early recognition by participating in the Y Combinator W20 batch, which helped accelerate its growth and visibility within the healthcare and industrial bio sectors.
Acquisition
As of the latest update, Volumetric has achieved acquisition status. This development marks a significant milestone in the company's journey, underscoring the value and impact of its 3D bioprinting technologies.